Abstracts tagged "prognostic factors and remission"

Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis
Tomokazu Nagakura¹, Takuma Ito², Masateru Kusuda², Tuyoshi Yamatou², Tomohiro Kubota², Yuuichi Yamasaki², Yukiko Nonaka², Tomoko Takezaki², Harumi Akaike³, Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, ²Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ³Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ⁴Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
Abstract Number: 2275 • 2017 ACR/ARHP Annual Meeting
Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Daniel B. Horton¹, Fenglong Xie², Melissa L. Mannion³, Sarah Ringold⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatrics, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Stopping medications is a priority for many patients with well-controlled JIA, but few factors predict favorable outcomes after discontinuation. We examined factors associated with…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Hilde B. Hammer², Till Uhlig¹, Desiree van der Heijde^1,3, Tore K Kvien¹ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…
Abstract Number: 509 • 2015 ACR/ARHP Annual Meeting
In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
Gilles Boire^1,2, Nathalie Carrier³, Artur de Brum-Fernandes^1,4, Patrick Liang^1,4, Ariel Masetto^2,5, Yuan Gui⁶, Jane Savill⁶, Sara Michienzi⁶, Henri Ménard⁷, Walter Maksymowych⁸ and Anthony Marotta⁶, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ³Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Advancements in RA treatment approaches with DMARDs and biological agents have enabled disease remission goals that were previously considered unattainable. The concept of "tight…
Abstract Number: 2379 • 2014 ACR/ARHP Annual Meeting
Minimal Radiographic Progression in RA Patients Receiving Routine Care in the Espoir Early Arthritis Cohort: Similar Prognosis According to 6 Different Remission Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Nancy University Hospital, Nancy, France, ⁵Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose Remission has become a more achievable goal in rheumatoid arthritis (RA). Several criteria for remission are available in RA, including one based on RAPID3…
Abstract Number: 1388 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis
Margarita Landi¹, Christian A. Waimann², Gustavo Citera³, O Cerda⁴, Federico Ceccatto⁵, Sergio Paira⁶, Francisco Caeiro⁷, Lucila Marino⁸, M Mamani⁹, Anastasia Secco⁹, G Crespo⁹, AC Alvarez¹⁰, Maria Haye Salinas⁷, A Alvarellos¹¹, Javier Rosa¹², Valeria Scaglioni¹³, Enrique R. Soriano¹⁴, Josefina Marcos¹⁵, Mercedes García¹⁵, A Salas¹⁵, Alejandro Martinez¹⁶, Rafael Chaparro del Moral¹⁷, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Veloso¹⁹, Ricardo V. Juárez²⁰, Maria Elena Crespo²¹, Ana Quinteros²², M Leal²², Gabriela Salvatierra²³, C Ledesma²³, Mónica P. Sacnun²⁴, R Quintana²⁵ and Marcelo Abdala²⁶, ¹Rheumatology, Instituto Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Hospital Olavarria, Olavarria, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁶Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁷Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Hospital Privado Centro Médico de, Córdoba, Argentina, ¹¹Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹³Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁵HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁷Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁸Centro Medico Privado de Reumatologia, Tucumán, Argentina, ¹⁹Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ²⁰Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ²¹Hospital Señor Del Milagro, Salta, Argentina, ²²Centro Integral de Reumatología, Tucumán, Argentina, ²³Instituto Provincial De Rehabilitación Integral, Stgo. del Estero, Argentina, ²⁴Hospital Provincial, Rosario, Argentina, ²⁵Hospital provincial, Rosario, Argentina, ²⁶Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose : Early and sustained remission has become the ultimate goal in early arthritis patients. The aim of our study was to estimate the prevalence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].